Overview
Balance Sheet
Cash Flow
Growth Analysis
2024
2023
2022
2021
2020
Profitability Metrics
Gross Margin
46.21%
Operating Margin
31.51%
Net Margin
23.97%
Efficiency Metrics
Revenue per Expense Ratio
1.46
R&D as % of Revenue
8.02%
Earnings Quality
EBITDA Margin
34.44%
Income Tax Rate
24.09%
EPS
6.1100000000
Balance Sheet Analysis
Current Ratio
0.87
Cash Ratio
0.37
Working Capital
$-23.41B
Debt to Equity
1.87
Debt to Assets
29.22%
Equity Ratio
15.60%
Cash Flow Analysis
Operating Cash Flow Ratio
30.24%
Free Cash Flow Ratio
27.83%
CapEx to Revenue
2.42%
Dividends Paid
$15.23B
Stock Buybacks
$94.95B
Total Shareholder Returns
$110.18B
Cash Position Change
-2.58%
Key Takeaways (2024 FY)
Increased dividend payments by 4.04%
Increased R&D investment by 4.86%
Detailed Growth Metrics
Core Performance
Revenue
2.02%
Net Income
-3.36%
EPS
-0.81%
Operating Income
7.80%
Operational Efficiency
R&D Expenses
4.86%
SG&A Expenses
4.67%
Operating Cash Flow
6.98%
Free Cash Flow
9.26%
Balance Sheet Health
Assets
3.52%
Debt
-4.01%
Book Value per Share
-5.97%
Inventory
15.08%
Shareholder Returns
Dividends per Share
4.04%
Shares Outstanding
-2.54%
Long Term Trends
3Y Revenue/Share
16.35%
5Y Revenue/Share
80.93%
3Y Dividend/Share
14.62%
5Y Dividend/Share
29.89%